131 related articles for article (PubMed ID: 34550341)
1. Selective HIF stabilization alleviates hepatocellular steatosis and ballooning in a rodent model of 70% liver resection.
Iesari S; Leclercq I; Joudiou N; Komuta M; Daumerie A; Ambroise J; Dili A; Feza-Bingi N; Xhema D; Bouzin C; Gallez B; Pisani F; Bonaccorsi-Riani E; Gianello P
Clin Sci (Lond); 2021 Oct; 135(19):2285-2305. PubMed ID: 34550341
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
3. Prolyl Hydroxylase Inhibition Enhances Liver Regeneration Without Induction of Tumor Growth.
Harnoss JM; Platzer LK; Burhenne J; Radhakrishnan P; Cai J; Strowitzki MJ; Weiss J; Ritter AS; Mollenhauer M; Schmidt T; Ulrich A; Haefeli WE; Schneider M
Ann Surg; 2017 Apr; 265(4):782-791. PubMed ID: 28266966
[TBL] [Abstract][Full Text] [Related]
4. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
5. HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis.
Su X; Xie Y; Zhang J; Li M; Zhang Q; Jin G; Liu F
Cell Death Dis; 2022 Oct; 13(10):861. PubMed ID: 36209275
[TBL] [Abstract][Full Text] [Related]
6. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
[TBL] [Abstract][Full Text] [Related]
7. FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization.
Tang D; Zhang J; Yan T; Wei J; Jiang X; Zhang D; Zhang Q; Jia J; Huang Y
Cell Physiol Biochem; 2018; 46(6):2460-2470. PubMed ID: 29742498
[TBL] [Abstract][Full Text] [Related]
8. The prolyl hydroxylase inhibitor roxadustat: Paradigm in drug discovery and prospects for clinical application beyond anemia.
Su K; Li Z; Yu Y; Zhang X
Drug Discov Today; 2020 Jul; 25(7):1262-1269. PubMed ID: 32380083
[TBL] [Abstract][Full Text] [Related]
9. Prolyl-4-Hydroxylases Inhibitor Stabilizes HIF-1α and Increases Mitophagy to Reduce Cell Death After Experimental Retinal Detachment.
Liu H; Zhu H; Li T; Zhang P; Wang N; Sun X
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1807-15. PubMed ID: 27082295
[TBL] [Abstract][Full Text] [Related]
10. Limited therapeutic efficacy of thrombopoietin on the regeneration of steatotic livers.
Abshagen K; Mertens F; Eipel C; Vollmar B
Int J Clin Exp Pathol; 2013; 6(9):1759-69. PubMed ID: 24040440
[TBL] [Abstract][Full Text] [Related]
11. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin promotes hepatic regeneration after extended liver resection in rats.
Schmeding M; Boas-Knoop S; Lippert S; Ruehl M; Somasundaram R; Dagdelen T; Neuhaus P; Neumann UP
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1125-31. PubMed ID: 18086112
[TBL] [Abstract][Full Text] [Related]
13. Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection.
Hamza AR; Krasniqi AS; Srinivasan PK; Afify M; Bleilevens C; Klinge U; Tolba RH
World J Gastroenterol; 2014 Oct; 20(40):14841-54. PubMed ID: 25356044
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease.
Schellinger IN; Cordasic N; Panesar J; Buchholz B; Jacobi J; Hartner A; Klanke B; Jakubiczka-Smorag J; Burzlaff N; Heinze E; Warnecke C; Raaz U; Willam C; Tsao PS; Eckardt KU; Amann K; Hilgers KF
Kidney Int; 2017 Mar; 91(3):616-627. PubMed ID: 27927598
[TBL] [Abstract][Full Text] [Related]
17. Reduction of obliterative bronchiolitis (OB) by prolyl-hydroxylase-inhibitors activating hypoxia-inducible transcription factors in an experimental mouse model.
Heim C; Motsch B; Jalilova S; Bernhardt WM; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM
Transpl Immunol; 2016 Nov; 39():66-73. PubMed ID: 27590486
[TBL] [Abstract][Full Text] [Related]
18. Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
Kabei K; Tateishi Y; Shiota M; Osada-Oka M; Nishide S; Uchida J; Nakatani T; Matsunaga S; Yamaguchi T; Tomita S; Miura K
J Pharmacol Sci; 2020 Mar; 142(3):93-100. PubMed ID: 31866051
[TBL] [Abstract][Full Text] [Related]
19. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy.
Veteläinen R; van Vliet AK; van Gulik TM
Ann Surg; 2007 Jan; 245(1):44-50. PubMed ID: 17197964
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of the manganese transporter SLC30A10 by hypoxia-inducible factors defines a homeostatic response to manganese toxicity.
Liu C; Jursa T; Aschner M; Smith DR; Mukhopadhyay S
Proc Natl Acad Sci U S A; 2021 Aug; 118(35):. PubMed ID: 34446561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
